{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00020219", "CSN": null, "TRF": "ORD_1349720_01", "MRN": "42698293", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1109565", "clinicalId": "1110936", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1349720_01", "SampleName": "US1297494.01", "Version": "0", "Sample": {"FM_Id": "ORD_1349720_01", "SampleId": "US1297494.01", "BlockId": "S111-14321C", "TRFNumber": "ORD_1349720_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_04_25", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "40", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-99188", "MRN": "42698293", "FullName": "\u9673\u79c0\u82b1", "FirstName": "Hsiu_Hua", "LastName": "Chen", "SubmittedDiagnosis": "Adenocarcinoma, Duodenum", "Gender": "Female", "DOB": "1955_11_03", "OrderingMD": "\u9673\u4e16\u6b3d", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Duodenum", "CollDate": "2022_04_08", "ReceivedDate": "2022-05-04 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Small Intestinal Carcinoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "20", "clinicalTrialCount": "14", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "BRD4", "isVUS": "true", "variantName": "V228I"}, {"geneName": "CUL3", "isVUS": "true", "variantName": "M454V"}, {"geneName": "DAXX", "isVUS": "true", "variantName": "E457del"}, {"geneName": "FLCN", "isVUS": "true", "variantName": "P28R"}, {"geneName": "MYC", "isVUS": "true", "variantName": "S298del"}, {"geneName": "SDHB", "isVUS": "true", "variantName": "C22S"}, {"geneName": "SMAD4", "isVUS": "true", "variantName": "A39G"}, {"geneName": "SOCS1", "isVUS": "true", "variantName": "T15I"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "CCND1", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "CCND1 encodes cyclin D1, a binding partner of the kinases CDK4 and CDK6, that regulates RB activity and cell cycle progression. Amplification of CCND1 has been positively correlated with cyclin D1 overexpression (Elsheikh et al., 2008; 17653856) and may lead to excessive proliferation (Fu et al., 2004; 15331580, Takahashi_Yanaga and Sasaguri, 2008; 18023328). In 1 study of small intestinal carcinomas, CCND1 amplification was reported in 3.4% of cases (Takeda et al., 2022; ASCO GI Abstract 642). Cyclin D1 expression has been reported in 33% of small bowel adenocarcinomas and 36% of small bowel adenomas compared with no expression detected in normal mucosa (Arber et al., 1997; 9298583). One study has reported increasing expression of cyclin D in small intestine adenomas and adenocarcinoma tumors; however, increased expression did not correlate with tumor progression (Arber et al., 1999; 10613343). Amplification or overexpression of CCND1 may predict sensitivity to CDK4/6 inhibitors, such as abemaciclib, palbociclib, and ribociclib (Juric et al., 2016; ASCO Abstract 568, Peguero et al., 2016; ASCO Abstract 2528, Tolaney et al., 2016; SABCS P4_22_12, Morschhauser et al., 2020; 32381571, Flaherty et al., 2012; 22090362, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Patnaik et al., 2016; 27217383, Leonard et al., 2012; 22383795), although as monotherapy these agents have shown limited activity in tumor types other than breast cancer (Dickler et al., 2017; 28533223, Patnaik et al., 2016; 27217383). In refractory advanced solid tumors with CCND1 (n=39) or CCND3 (n=1) amplification and retinoblastoma protein expression, palbociclib resulted in SD for 39% (14/36) of patients and a median PFS of 1.8 months in the NCI_MATCH trial (Clark et al., 2019; AACR Abstract LB_010/2); 4 patients (13%, 4/36 overall) with squamous cell carcinomas (lung, esophageal, or laryngeal) or adenoid cystic carcinoma experienced prolonged SD in this study (Clark et al., 2019; AACR Abstract LB_010/2). Among 9 patients with CCND1_amplified advanced solid tumors, 1 patient with bladder cancer responded to ribociclib in a Phase 2 trial (Peguero et al., 2016; ASCO Abstract 2528). CCND1 amplification may predict worse outcomes on immune checkpoint inhibitors (anti_PD_1/PD_L1/CTLA_4) in solid tumors on the basis of 2 meta_analyses (Chen et al., 2020; 32903763, Litchfield et al., 2021; 33508232); in these studies, CCND1 amplification was associated with significantly decreased response rate (Litchfield et al., 2021; 33508232) and OS (HR=1.6_2.0)(Chen et al., 2020; 32903763, Litchfield et al., 2021; 33508232) across various tumor types and significantly shorter OS specifically in urothelial carcinoma (HR=2.2_3.6), melanoma (HR=1.6_2.5), and solid tumors harboring elevated TMB (HR=2.8)(Chen et al., 2020; 32903763, Litchfield et al., 2021; 33508232).", "Include": "true", "ClinicalTrialNote": "CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single_agent CDK4/6 inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04282031", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT05252416", "Include": "true"}, {"nctId": "NCT02896335", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "FGFR2", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "FGFR2 encodes a tyrosine kinase cell surface receptor, which plays an important role in cell differentiation, growth, and angiogenesis (Powers et al., 2000; 11021964, Turner and Grose, 2010; 20094046). FGFR2 amplification has been reported in a variety of cancer types (Gao et al., 2013; 23550210) and has been shown to correlate with increased mRNA and protein expression (Pearson et al., 2016; 27179038, Tokunaga et al., 2016; 26933914). Higher level, clonal FGFR2 amplification has been reported to correlate with higher response rates to FGFR inhibitors (Pearson et al., 2016; 27179038, Andr\u00e9 et al., 2013; 23658459). FGFR2 mutation has been reported in 4% (1/28) of small intestine adenocarcinoma cases (Alvi et al., 2015; 26315110) and in 2% (1/48) of small intestine neuroendocrine tumors (Banck et al., 2013; 23676460). Published data investigating the prognostic implications of FGFR2 alteration in small intestine tumors are limited (PubMed, Mar 2022). FGFR2 activating mutations, amplifications, or fusions may confer sensitivity to selective FGFR inhibitors such as erdafitinib (Tabernero et al., 2015; 26324363, Siefker_Radtke et al., 2018; ASCO Abstract 4503, Soria et al., 2017; ASCO Abstract 4074, Park et al., 2019; ASCO Abstract 4117), pemigatinib (Hollebecque et al., 2019; ESMO Abstract 720P, Krook et al., 2019; 31371345, Abou_Alfa et al., 2020; 32203698, Kuboki et al., 2019; JSMO Abstract P1_156), infigratinib (Nogova et al., 2016; 27870574, Javle et al., 2021; ASCO GI Abstract 265), E7090 (Morizane et al., 2020; ASCO GI Abstract 538), AZD4547 (Pearson et al., 2016; 27179038, Van Cutsem et al., 2017; 29177434, Aggarwal et al., 2019; 31195180, Chae et al., 2018; ASCO Abstract 2503), Debio 1347 (Voss et al., 2019; 30745300, Clearly et al., 2021; 33926920), rogaratinib (Schuler et al., 2019; 31405822), futibatinib (Bahleda et al., 2018; AACR Abstract CT121, Goyal et al., 2019; 31109923, Tran et al., 2018; ESMO Abstract 155O), ICP192 (Guo et al., 2021; ASCO Abstract 4092), and derazantinib (Mazzaferro et al., 2019; 30420614) as well as to the multikinase inhibitors pazopanib (Borad et al., 2014; 24550739, Liao et al., 2013; 23786770) and ponatinib (Gozgit et al., 2012; 22238366). In a Phase 2 study of the FGFR inhibitor AZD4547, responses were reported in 33% (3/9) of patients with FGFR2_amplified gastroesophageal cancer; in this study, higher_level amplification correlated with higher likelihood of response to FGFR inhibitors (Pearson et al., 2016; 27179038). However, a randomized Phase 2 study of AZD4547 compared with paclitaxel for the treatment of patients with advanced stomach adenocarcinoma harboring FGFR2 amplification or polysomy reported no significant increase in median PFS, median OS, or ORR (Van Cutsem et al., 2017; 29177434).", "Include": "true", "ClinicalTrialNote": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04977453", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03564691", "Include": "true"}, {"nctId": "NCT04008797", "Include": "true"}, {"nctId": "NCT04565275", "Include": "true"}, {"nctId": "NCT04965818", "Include": "true"}, {"nctId": "NCT04729348", "Include": "true"}, {"nctId": "NCT02856425", "Include": "true"}, {"nctId": "NCT01543763", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "C11orf30 (EMSY)", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "EMSY, also known as C11orf30, encodes a BRCA2_interacting protein with roles in transcriptional regulation (Varier et al., 2016; 26841866, Hughes_Davies et al., 2003; 14651845). Preclinical studies have suggested that EMSY binds to and suppresses the function of BRCA2, and EMSY overexpression may therefore mimic BRCA2 inactivation (Cousineau and Belmaaza, 2011; 21409565, Hughes_Davies et al., 2003; 14651845). Amplification of the EMSY gene correlates with increased mRNA expression (Wilkerson et al., 2011; 21735447, van Hattem et al., 2008; 18787609), although conflicting data have been reported (Shih et al., 2005; 16172393). The functional consequences of other EMSY alterations have not been extensively studied (PubMed, 2022). In the TCGA datasets, EMSY amplification has been most frequently observed in ovarian carcinoma (8%)(Cancer Genome Atlas Research Network., 2011; 21720365), breast invasive carcinoma (6%)(Cancer Genome Atlas Network., 2012; 23000897), esophageal carcinoma (5%)(cBioPortal, 2022), and head and neck squamous cell carcinoma (3.5%)(HNSCC_Cancer Genome Atlas Network., 2015; 25631445, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). EMSY overexpression has been primarily reported in breast and high grade ovarian cancers, where it is implicated in BRCA2 inactivation and correlates with poor prognosis or advanced disease (Wilkerson et al., 2011; 21735447, Brown et al., 2008; 18314909, Brown et al., 2010; 19636701, Altinisik et al., 2011; 20349280, Madjd et al., 2014; 24641409, Bane et al., 2011; 21327470, Rodriguez et al., 2004; 15355907, Hughes_Davies et al., 2003; 14651845). The consequences of EMSY alterations in other solid tumors or hematologic malignancies have not been studied in detail in the scientific literature (PubMed, 2022). EMSY overexpression in breast cancer cell lines has been reported to mimic the effects of inactivating BRCA2 mutations (Cousineau and Belmaaza, 2011; 21409565). Unlike BRCA2 inactivation, which predicts sensitivity to DNA repair_associated inhibitors such as the PARP inhibitor olaparib (Dedes et al., 2011; 21487248, Ihnen et al., 2013; 23729402), EMSY amplification in breast cancer lines was not associated with enhanced sensitivity to this drug in one preclinical study (Wilkerson et al., 2011; 21735447). There are no therapies that target EMSY alterations.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CCND3", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "CCND3 encodes cyclin D3, a G1/S_specific cell cycle regulator. Cyclin D3 interacts with and regulates the cyclin_dependent kinases CDK4 and CDK6, resulting in the phosphorylation and inactivation of Rb and the progression of the cell cycle (Sridhar et al., 2006; 16584130). CCND3 amplification has been associated with increased cyclin D3 expression (Kusugai et al., 2005; 16322284). The frequency of CCND3 amplification in carcinomas of the small intestine has not been evaluated (PubMed, cBioPortal, Jun 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of CCND3 alterations in duodenum and small intestine carcinomas are limited (PubMed, Jun 2021). In a study of 32 mixed gastric carcinomas, overexpression of CCND3 correlated with moderate tumor differentiation and poor survival; CCND3 overexpression was not reported in the gastric_intestinal adenocarcinomas analyzed in this study (Shan et al., 2017; 28943959). On the basis of preclinical studies, amplification or activation of CCND3 may predict sensitivity to CDK4/6 inhibitors, such as abemaciclib (Gong et al. 2017; 29232554, Tanaka et al., 2020; 31849147) and palbociclib (Schmitz et al., 2012; 22885699, Choi et al., 2012; 23079655, Sawai et al., 2012; 23079656); however, 1 preclinical study implicated CCND3 overexpression as a potential mechanism of resistance to palbociclib (Ketzer et al., 2022; 35013097).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FGF19", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "FGF19 encodes fibroblast growth factor 19, an FGFR4 ligand involved with bile acid synthesis and hepatocyte proliferation in the liver (Xie et al., 1999; 10525310, Hagel et al., 2015; 25776529). FGF19 lies in a region of chromosome 11q13 that also contains FGF3, FGF4, and CCND1; this region is frequently amplified in a diverse range of malignancies (Katoh et al., 2002; 12429977). Correlation between FGF19 amplification and protein expression has been reported in hepatocellular carcinoma (HCC)(Kan et al., 2013; 23788652), lung squamous cell carcinoma (Li et al., 2020; 32111983, Caruso et al., 2019; 31063779), and head and neck squamous cell carcinoma (HNSCC)(Gao et al., 2019; 30518874), but was not observed in other cancers (Sawey et al., 2011; 21397858, Kanzaki et al., 2021; 33674622). For patients with solid tumors, FGF19 amplification has been reported most frequently in breast cancer (17%), head and neck cancer (12%), lung squamous cell carcinoma (SCC; 12%), and urothelial carcinoma cancer (11%)(cBio_Zehir et al., 2017; 28481359, cBio_Cancer Genome Atlas Research Network, 2012; 22960745, cBio_Robertson et al., 2017; 28988769). FGF19 mutations are rare in solid tumors (cBio_Zehir et al., 2017; 28481359). FGF19 expression or amplification has been associated with poor prognosis in hepatocellular carcinoma (HCC)(Miura et al., 2012; 22309595, Kang et al., 2019; 30815392), and in prostate cancer following radical prostatectomy (Nagamatsu et al., 2015; 25854696). Studies suggest FGF19 expression may also be a poor prognostic indicator in head and neck squamous cell carcinoma (HNSCC)(Gao et al., 2019; 30518874) and lung SCC (Li et al., 2020; 32111983). A Phase 1 study of the FGFR4 inhibitor fisogatinib (BLU_554) for patients with advanced hepatocellular carcinoma (HCC) reported a 17% ORR (11/66, 1 CR, ongoing for >1.5 years) and 3.3_month PFS for FGF19 IHC\u2013positive patients; patients with negative or unknown FGF19 IHC scores experienced poorer outcomes (0% ORR, 2.3_month PFS)(Kim et al., 2019; 31575541). A Phase 1/2 study evaluating another FGFR4 inhibitor, FGF401, demonstrated an ORR of 7.5% (4/53) and SD rate of 53% (28/53) for patients with HCC (Chan et al., 2017; AACR Abstract CT106). A Phase 1 study of the FGFR4 inhibitor H3B_6527 reported a 17% ORR (OS of 10.3 months, 46% clinical benefit rate) among patients with HCC; enrollment of patients with intrahepatic cholangiocarcinoma (ICC) was suspended due to efficacy (Macarulla et al., 2021; ASCO Abstract 4090). A retrospective analysis reported that 50% (2/4) of patients with HCC harboring FGF19 amplification experienced a CR to sorafenib (Kaibori et al., 2016; 27384874), though another retrospective study found patients with higher pretreatment serum levels of FGF19 experienced reduced benefit from sorafenib compared with those with lower serum FGF19 (PFS of 86 vs. 139 days, OS of 353 vs. 494 days); no difference was observed for lenvatinib (Kanzaki et al., 2021; 33674622). A patient with head and neck squamous cell carcinoma (HNSCC) with 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) amplification experienced a CR lasting 9 months from a pan_FGFR inhibitor (Dumbrava et al., 2018; 31123723).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FGF3", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "FGF3 encodes fibroblast growth factor 3, a growth factor that plays a central role in development of the inner ear. Germline mutations in FGF3 give rise to an autosomal recessive syndrome characterized by microdontia, deafness, and complete lack of inner ear structures (Tekin et al., 2007; 17236138). FGF3 lies in a region of chromosome 11q13 that also contains FGF19, FGF4, and CCND1, the latter gene encoding cyclin D1, a key regulator of cell cycle progression. This chromosomal region is frequently amplified in a diverse range of malignancies (Fu et al., 2004; 15331580). There are no targeted therapies that directly address genomic alterations in FGF3. Inhibitors of FGF receptors, however, are undergoing clinical trials in a number of different cancers. Limited data suggest that pan_FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan_FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR (Dumbrava et al., 2018; doi/full/10.1200/PO.18.00100).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FGF4", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "FGF4 encodes fibroblast growth factor 4, which plays a central role in development of the teeth (Kratochwil et al., 2002; 12502739) and acts synergistically with other FGFs and SHH (sonic hedgehog) to regulate limb outgrowth in vertebrate development (Scherz et al., 2004; 15256670). FGF4 lies in a region of chromosome 11q13 that also contains FGF19, FGF3, and CCND1, the latter gene encoding cyclin D1, a key regulator of cell cycle progression. Amplification of FGF4, along with that of FGF3, FGF19, and CCND1, has been reported in a variety of cancers (Fu et al., 2004; 15331580, Zaharieva et al., 2003; 14648664, Arai et al., 2003; 14499691, Ribeiro et al., 2014; 24477574, Arao et al., 2013; 22890726, Schulze et al., 2015; 25822088) and may confer sensitivity to the multi_kinase inhibitor sorafenib (Arao et al., 2013; 22890726). FGF4 lies in a region of chromosome 11q13 that also contains FGF19, FGF3, and CCND1, the latter gene encoding cyclin D1, a key regulator of cell cycle progression. This chromosomal region is frequently amplified in a diverse range of malignancies (Fu et al., 2004; 15331580) including esophageal carcinoma (35%), head and neck squamous cell carcinoma (HNSCC; 24%), breast invasive carcinoma (14%), lung squamous cell carcinoma (13%), cholangiocarcinoma (11%), bladder urothelial carcinoma (10%), stomach adenocarcinoma (7%), skin melanoma (5%), and hepatocellular carcinoma (HCC; 5%), however FGF4 amplification is rare in hematopoietic and lymphoid malignancies, reported in less than 1% of samples analyzed (cBioPortal, Jan 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). FGF4 amplification and overexpression was associated with cell sensitivity to the multikinase inhibitor sorafenib in preclinical studies (Arao et al., 2013; 22890726, Yamada et al., 2015; 25885470) and amplification of FGF4/FGF3 in HCC significantly correlated with patient response to sorafenib (p=0.006)(Arao et al., 2013; 22890726). Limited data suggest that pan_FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan_FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR (Dumbrava et al., 2018; doi/full/10.1200/PO.18.00100).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "GATA6", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "GATA6 encodes a zinc finger transcription factor, which is involved in the development of several tissues and is expressed in proliferating cells throughout the intestinal tract (Zheng et al., 2010; 21779441). GATA6 has been described as both a tumor suppressor and an oncogene, which may be dependent on the tumor type. Amplification of the GATA6 locus, 18q11.2, has been reported with highest incidences in esophageal adenocarcinomas (21%, 18/85) and pancreatobiliary carcinomas (19%, 7/37)(Lin et al., 2012; 22375031, Kwei et al., 2008; 18535672), and at lower rates in small intestine cancer (5.5%)(Takeda et al., 2022; ASCO GI Abstract 642), urothelial bladder carcinoma (3.9%), lung adenocarcinoma (1.7%), and ovarian carcinoma (1.8%)(cBio_The Cancer Genome Atlas Research Network, 2014; 24476821, cBio_The Cancer Genome Atlas Research Network, 2014; 25079552, cBio_The Cancer Genome Atlas Research Network, 2011; 21720365). While low GATA6 expression correlated with poor prognosis for patients with non_small cell lung cancer (NSCLC) (Yu et al., 2022; DOI: 10.3892/etm.2022.11210, Chen et al., 2020; 32596145), gastric cancer (Liu et al., 2019; 30674866), bladder cancer (Wang et al., 2020; 32103545), or esophageal adenocarcinomas without neoadjuvant treatment (Plum et al., 2021; 33300112), high GATA6 expression has been associated with poor outcome for patients with colon cancer (Shen et al., 2013; 23784465), breast cancer (Song et al., 2015; 26505174), ovarian cancer (Shen et al., 2019; 30633927), cholangiocarcinoma (Tian et al., 2013; 23313142), and NSCLC following EGFR_TKI treatment (Ma et al., 2019; 31092103). There are no targeted therapies available to address genomic alterations in GATA6. Patients with GATA6_high pancreatic tumors exhibited better clinical outcomes following treatment with adjuvant chemotherapy (p=0.003) or first_line folfirinox (HR=1.90, p=0.025) treatment compared with low GATA6 expressing tumors, while no difference was observed for patients treated with gemcitabine (Duan et al., 2021; 34294813, Martinelli et al., 2017; 27325420).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_H has been frequently reported in carcinomas of the small bowel (Alvi et al., 2015; 26315110, Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06)(Blaker et al., 2002; 11791187, Bruecki et al., 2004; 14732226, Hibi et al., 1995; 7775257, Overman et al., 2010; 19935793, Rashid et al., 1997; 9207270, Wheeler et al., 2002; 11788563), with larger studies reporting a rate of 10.4_19.6% of small intestine carcinomas (Planck et al., 2003; 12627520, Michel et al., 2010; 19852062, Ruemmele et al., 2009; 19252434). MSI_H small intestine adenocarcinomas were reported to be higher tumor grade and associated with longer median overall survival (49.6 vs. 23.2 months) than MSS tumors (Bruecki et al., 2004; 14732226, Ruemmele et al., 2009; 19252434, Muneyuki et al., 2000; 11117578, Agaramet al., 2010; 20395525). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "NRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "NRAS encodes a member of the RAS family of small GTPases that mediate transduction of growth signals. Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways (Pylayeva_Gupta et al., 2011; 21993244). NRAS has been reported to be amplified in cancer (Gao et al., 2013; 23550210), and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). NRAS mutation has been observed in 0_3.5% of small intestine adenocarcinomas (Younes et al., 1997; 9128999, Alvi et al., 2015; 26315110). Published data investigating the prognostic implications of NRAS alteration in small intestine carcinoma are limited (PubMed, Feb 2021). On the basis of clinical evidence in hematologic malignancies (Slosberg et al., 2018; 29765547, Ravandi et al., 2015; 26657199, Maiti et al., 2019; 30635233, Khanna et al., 2015; 26870618, Heuck et al., 2014; ASH Abstract 4775) and solid tumors (Slosberg et al., 2018; 29765547, Wu et al., 2018; WCLC Abstract P1.01_97, Dummer et al., 2017; 28284557, Ascierto et al., 2013; 23414587) as well as preclinical evidence (Burgess et al., 2014; 25361812, Ohashi et al., 2013; 23515407, Posch et al., 2015; 26016894, Pylayeva_Gupta et al., 2011; 21993244, Vogel et al., 2015; 25728708), NRAS activating alterations may predict sensitivity to MEK inhibitors, such as trametinib, cobimetinib, and binimetinib. Preclinical data in cancer cell lines indicates that NRAS mutation predicts sensitivity to the PI3K_alpha_specific inhibitor alpelisib (Fritsch et al., 2014; 24608574).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "R335fs*10", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R335fs*10"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 alterations have been reported in 50_60% of small intestine cancer cases (Alvi et al., 2015; 26315110, Takeda et al., 2022; ASCO GI Abstract 642), and mutations were observed in 1 of 10 duodenal carcinomas and 3 of 10 jejunal/ileal carcinomas in another study (Muneyuki et al., 2000; 11117578). Loss of 17p heterozygosity, where the TP53 gene resides, has been observed in 20_67% of duodenal and 20% of ileal/jejunal carcinomas (Achille et al., 1998; 9514055, Muneyuki et al., 2000; 11117578). Expression of p53 has been observed in 24_53.3% of small intestine carcinomas (Arai et al., 1997; 9033644, Wheeler et al., 2002; 11788563, Nishiyama et al., 2002; 11836595). In one study, expression of p53 was more common in poorly differentiated tumors (71%) as compared with well_differentiated cases (30%) (Nishiyama et al., 2002; 11836595). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "03", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "03"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Small intestinal adenocarcinoma harbors a median TMB of 4.5 mutations per megabase (muts/Mb), with 12% of cases exhibiting a TMB \u226510muts/Mb (Takeda et al., 2022; ASCO GI Abstract 642) and 8.3_9.5% of cases harboring a TMB >20 muts/Mb (FMI_Chalmers et al., 2017; 28420421, Shrock et al., 2017; 28617917). In 1 study, small bowel adenocarcinomas were significantly enriched for high TMB relative to colorectal cancer or gastric cancer, and high TMB was more frequent in unspecified small bowel adenocarcinoma than in duodenal adenocarcinoma (Shrock et al., 2017; 28617917). Published data investigating the prognostic implications of TMB in small intestinal cancers are generally limited (PubMed, Sep 2021). One study reported that amongst a cohort of patients with small bowel cancer (n=23), high TMB (>10 Mut/Mb) was associated with favorable OS (p<0.05) (Tsuboi et al., 2021; 34014970). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB \u226510 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB \u226510 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "CCND1", "Alteration": "amplification", "Title": "A Study of BPI_1178 in Patients With Advanced Solid Tumor and HR+/HER2_ Breast Cancer", "StudyPhase": "PHASE 1/2", "Target": "CDK6, CDK4, ER, Aromatase", "Locations": "Shanghai (China)", "NCTID": "NCT04282031", "Note": "CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single_agent CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND1", "Alteration": "amplification", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single_agent CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND1", "Alteration": "amplification", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single_agent CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND1", "Alteration": "amplification", "Title": "(VELA) Study of BLU_222 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ER, CDK4, CDK6, CDK2", "Locations": "Massachusetts", "NCTID": "NCT05252416", "Note": "CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single_agent CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND1", "Alteration": "amplification", "Title": "Palbociclib In Progressive Brain Metastases", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT02896335", "Note": "CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single_agent CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "amplification", "Title": "GI_101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1, CTLA_4", "Locations": "Daejeon (Korea, Republic of), Suwon_si (Korea, Republic of), Seoul (Korea, Republic of)", "NCTID": "NCT04977453", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "amplification", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "amplification", "Title": "Study of MK_4830 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_4830_001)", "StudyPhase": "PHASE 1", "Target": "ITL4, FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1", "Locations": "Seoul (Korea, Republic of), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Haifa (Israel), Warszawa (Poland), Gdansk (Poland), Heraklion (Greece), Washington, Hospitalet de Llobregat (Spain)", "NCTID": "NCT03564691", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "amplification", "Title": "A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor", "StudyPhase": "PHASE 1", "Target": "CBP, Beta_catenin, FGFRs, RET, PDGFRA, VEGFRs, KIT", "Locations": "Osakasayama (Japan), Chuo_Ku (Japan), Kashiwa (Japan)", "NCTID": "NCT04008797", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "amplification", "Title": "A Study of ICP_192 in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "FGFR2, FGFR1, FGFR3, FGFR4", "Locations": "Macquarie Park (Australia), Melbourne (Australia), Clayton (Australia), Frankston (Australia), Colorado, Minnesota, Arizona, Ohio, Florida", "NCTID": "NCT04565275", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "amplification", "Title": "Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer", "StudyPhase": "PHASE 1/2", "Target": "MEK, FGFRs", "Locations": "California, Indiana, Texas", "NCTID": "NCT04965818", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "amplification", "Title": "Pembrolizumab And Lenvatinib In Leptomeningeal Metastases", "StudyPhase": "PHASE 2", "Target": "PD_1, KIT, VEGFRs, FGFRs, PDGFRA, RET", "Locations": "Massachusetts", "NCTID": "NCT04729348", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "amplification", "Title": "Trial Of Pembrolizumab And Nintedanib", "StudyPhase": "PHASE 1", "Target": "FGFR1, LCK, SRC, VEGFRs, FGFR2, FGFR3, FLT3, LYN, PD_1", "Locations": "Villejuif (France)", "NCTID": "NCT02856425", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "amplification", "Title": "Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI_24781 in Patients With Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "HDAC, FGFR3, KIT, FGFR1, VEGFRs, FGFR2", "Locations": "California", "NCTID": "NCT01543763", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "11021964", "FullCitation": "Powers CJ, et al. Endocr. Relat. Cancer (2000) pmid: 11021964", "Include": "true"}, {"number": "1", "ReferenceId": "20094046", "FullCitation": "Turner N, et al. Nat. Rev. Cancer (2010) pmid: 20094046", "Include": "true"}, {"number": "2", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "3", "ReferenceId": "27179038", "FullCitation": "Pearson A, et al. Cancer Discov (2016) pmid: 27179038", "Include": "true"}, {"number": "4", "ReferenceId": "26933914", "FullCitation": "Tokunaga R, et al. Oncotarget (2016) pmid: 26933914", "Include": "true"}, {"number": "5", "ReferenceId": "23658459", "FullCitation": "Andr\u00e9 F, et al. Clin. Cancer Res. (2013) pmid: 23658459", "Include": "true"}, {"number": "6", "ReferenceId": "26315110", "FullCitation": "Alvi MA, et al. Oncotarget (2015) pmid: 26315110", "Include": "true"}, {"number": "7", "ReferenceId": "23676460", "FullCitation": "Banck MS, et al. J. Clin. Invest. (2013) pmid: 23676460", "Include": "true"}, {"number": "8", "ReferenceId": "26324363", "FullCitation": "Tabernero J, et al. J. Clin. Oncol. (2015) pmid: 26324363", "Include": "true"}, {"number": "9", "ReferenceId": "31371345", "FullCitation": "Krook MA, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 31371345", "Include": "true"}, {"number": "10", "ReferenceId": "32203698", "FullCitation": "Abou_Alfa GK, et al. Lancet Oncol. (2020) pmid: 32203698", "Include": "true"}, {"number": "11", "ReferenceId": "27870574", "FullCitation": "Nogova L, et al. J. Clin. Oncol. (2017) pmid: 27870574", "Include": "true"}, {"number": "12", "ReferenceId": "29177434", "FullCitation": "Van Cutsem E, et al. Ann. Oncol. (2017) pmid: 29177434", "Include": "true"}, {"number": "13", "ReferenceId": "31195180", "FullCitation": "Aggarwal C, et al. J Thorac Oncol (2019) pmid: 31195180", "Include": "true"}, {"number": "14", "ReferenceId": "30745300", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2019) pmid: 30745300", "Include": "true"}, {"number": "15", "ReferenceId": "33926920", "FullCitation": "Cleary JM, et al. Cancer Discov (2021) pmid: 33926920", "Include": "true"}, {"number": "16", "ReferenceId": "31405822", "FullCitation": "Schuler M, et al. Lancet Oncol. (2019) pmid: 31405822", "Include": "true"}, {"number": "17", "ReferenceId": "31109923", "FullCitation": "Goyal L, et al. Cancer Discov (2019) pmid: 31109923", "Include": "true"}, {"number": "18", "ReferenceId": "30420614", "FullCitation": "Mazzaferro V, et al. Br. J. Cancer (2019) pmid: 30420614", "Include": "true"}, {"number": "19", "ReferenceId": "24550739", "FullCitation": "Borad MJ, et al. PLoS Genet. (2014) pmid: 24550739", "Include": "true"}, {"number": "20", "ReferenceId": "23786770", "FullCitation": "Liao RG, et al. Cancer Res. (2013) pmid: 23786770", "Include": "true"}, {"number": "21", "ReferenceId": "22238366", "FullCitation": "Gozgit JM, et al. Mol. Cancer Ther. (2012) pmid: 22238366", "Include": "true"}, {"number": "22", "ReferenceId": "17653856", "FullCitation": "Elsheikh S, et al. Breast Cancer Res. Treat. (2008) pmid: 17653856", "Include": "true"}, {"number": "23", "ReferenceId": "15331580", "FullCitation": "Fu M, et al. Endocrinology (2004) pmid: 15331580", "Include": "true"}, {"number": "24", "ReferenceId": "18023328", "FullCitation": "Takahashi_Yanaga F, et al. Cell. Signal. (2008) pmid: 18023328", "Include": "true"}, {"number": "25", "ReferenceId": "9298583", "FullCitation": "Arber N, et al. Cancer Epidemiol. Biomarkers Prev. (1997) pmid: 9298583", "Include": "true"}, {"number": "26", "ReferenceId": "10613343", "FullCitation": "Arber N, et al. Cancer Epidemiol. Biomarkers Prev. (1999) pmid: 10613343", "Include": "true"}, {"number": "27", "ReferenceId": "32381571", "FullCitation": "Morschhauser F, et al. Haematologica (2020) pmid: 32381571", "Include": "true"}, {"number": "28", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "29", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "30", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "31", "ReferenceId": "27217383", "FullCitation": "Patnaik A, et al. Cancer Discov (2016) pmid: 27217383", "Include": "true"}, {"number": "32", "ReferenceId": "22383795", "FullCitation": "Leonard JP, et al. Blood (2012) pmid: 22383795", "Include": "true"}, {"number": "33", "ReferenceId": "28533223", "FullCitation": "Dickler MN, et al. Clin. Cancer Res. (2017) pmid: 28533223", "Include": "true"}, {"number": "34", "ReferenceId": "32903763", "FullCitation": "Chen Y, et al. Front Immunol (2020) pmid: 32903763", "Include": "true"}, {"number": "35", "ReferenceId": "33508232", "FullCitation": "Litchfield K, et al. Cell (2021) pmid: 33508232", "Include": "true"}, {"number": "36", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "37", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "38", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "39", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "40", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "41", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "42", "ReferenceId": "11791187", "FullCitation": "Bl\u00e4ker H, et al. Oncogene (2002) pmid: 11791187", "Include": "true"}, {"number": "43", "ReferenceId": "14732226", "FullCitation": "Brueckl WM, et al. Cancer Lett. (2004) pmid: 14732226", "Include": "true"}, {"number": "44", "ReferenceId": "7775257", "FullCitation": "Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257", "Include": "true"}, {"number": "45", "ReferenceId": "19935793", "FullCitation": "Overman MJ, et al. Br. J. Cancer (2010) pmid: 19935793", "Include": "true"}, {"number": "46", "ReferenceId": "9207270", "FullCitation": "Rashid A, et al. Gastroenterology (1997) pmid: 9207270", "Include": "true"}, {"number": "47", "ReferenceId": "11788563", "FullCitation": "Wheeler JM, et al. Gut (2002) pmid: 11788563", "Include": "true"}, {"number": "48", "ReferenceId": "12627520", "FullCitation": "Planck M, et al. Cancer (2003) pmid: 12627520", "Include": "true"}, {"number": "49", "ReferenceId": "19852062", "FullCitation": "Michel S, et al. Mol. Carcinog. (2010) pmid: 19852062", "Include": "true"}, {"number": "50", "ReferenceId": "19252434", "FullCitation": "Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434", "Include": "true"}, {"number": "51", "ReferenceId": "11117578", "FullCitation": "Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578", "Include": "true"}, {"number": "52", "ReferenceId": "20395525", "FullCitation": "Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525", "Include": "true"}, {"number": "53", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "54", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "55", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "56", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "57", "ReferenceId": "12502739", "FullCitation": "Kratochwil K, et al. Genes Dev. (2002) pmid: 12502739", "Include": "true"}, {"number": "58", "ReferenceId": "15256670", "FullCitation": "Scherz PJ, et al. Science (2004) pmid: 15256670", "Include": "true"}, {"number": "59", "ReferenceId": "14648664", "FullCitation": "Zaharieva BM, et al. J. Pathol. (2003) pmid: 14648664", "Include": "true"}, {"number": "60", "ReferenceId": "14499691", "FullCitation": "Arai H, et al. Cancer Genet. Cytogenet. (2003) pmid: 14499691", "Include": "true"}, {"number": "61", "ReferenceId": "24477574", "FullCitation": "Ribeiro IP, et al. Tumour Biol. (2014) pmid: 24477574", "Include": "true"}, {"number": "62", "ReferenceId": "22890726", "FullCitation": "Arao T, et al. Hepatology (2013) pmid: 22890726", "Include": "true"}, {"number": "63", "ReferenceId": "25822088", "FullCitation": "Schulze K, et al. Nat. Genet. (2015) pmid: 25822088", "Include": "true"}, {"number": "64", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "65", "ReferenceId": "25885470", "FullCitation": "Yamada T, et al. BMC Cancer (2015) pmid: 25885470", "Include": "true"}, {"number": "66", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "67", "ReferenceId": "24071852", "FullCitation": "Zack TI, et al. Nat. Genet. (2013) pmid: 24071852", "Include": "true"}, {"number": "68", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "69", "ReferenceId": "9128999", "FullCitation": "Younes N, et al. Cancer (1997) pmid: 9128999", "Include": "true"}, {"number": "70", "ReferenceId": "29765547", "FullCitation": "Slosberg ED, et al. Oncotarget (2018) pmid: 29765547", "Include": "true"}, {"number": "71", "ReferenceId": "26657199", "FullCitation": "Ravandi F, et al. Blood Cancer J (2015) pmid: 26657199", "Include": "true"}, {"number": "72", "ReferenceId": "30635233", "FullCitation": "Maiti A, et al. Clin Lymphoma Myeloma Leuk (2019) pmid: 30635233", "Include": "true"}, {"number": "73", "ReferenceId": "26870618", "FullCitation": "Khanna V, et al. Cureus (2015) pmid: 26870618", "Include": "true"}, {"number": "74", "ReferenceId": "28284557", "FullCitation": "Dummer R, et al. Lancet Oncol. (2017) pmid: 28284557", "Include": "true"}, {"number": "75", "ReferenceId": "23414587", "FullCitation": "Ascierto PA, et al. Lancet Oncol. (2013) pmid: 23414587", "Include": "true"}, {"number": "76", "ReferenceId": "25361812", "FullCitation": "Burgess MR, et al. Blood (2014) pmid: 25361812", "Include": "true"}, {"number": "77", "ReferenceId": "23515407", "FullCitation": "Ohashi K, et al. Clin. Cancer Res. (2013) pmid: 23515407", "Include": "true"}, {"number": "78", "ReferenceId": "26016894", "FullCitation": "Posch C, et al. J. Invest. Dermatol. (2015) pmid: 26016894", "Include": "true"}, {"number": "79", "ReferenceId": "25728708", "FullCitation": "Vogel CJ, et al. Pigment Cell Melanoma Res (2015) pmid: 25728708", "Include": "true"}, {"number": "80", "ReferenceId": "24608574", "FullCitation": "Fritsch C, et al. Mol. Cancer Ther. (2014) pmid: 24608574", "Include": "true"}, {"number": "81", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "82", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "83", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "84", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "85", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "86", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "87", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "88", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "89", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "90", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "91", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "92", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "93", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "94", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "95", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "96", "ReferenceId": "28617917", "FullCitation": "Schrock AB, et al. JAMA Oncol (2017) pmid: 28617917", "Include": "true"}, {"number": "97", "ReferenceId": "34014970", "FullCitation": "Tsuboi A, et al. PLoS One (2021) pmid: 34014970", "Include": "true"}, {"number": "98", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "99", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "100", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "101", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "102", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "103", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "104", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "105", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "106", "ReferenceId": "17236138", "FullCitation": "Tekin M, et al. Am. J. Hum. Genet. (2007) pmid: 17236138", "Include": "true"}, {"number": "107", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "108", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "109", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "110", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "111", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "112", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "113", "ReferenceId": "9514055", "FullCitation": "Achille A, et al. Br. J. Cancer (1998) pmid: 9514055", "Include": "true"}, {"number": "114", "ReferenceId": "9033644", "FullCitation": "Arai M, et al. Int. J. Cancer (1997) pmid: 9033644", "Include": "true"}, {"number": "115", "ReferenceId": "11836595", "FullCitation": "Nishiyama K, et al. Oncol. Rep. () pmid: 11836595", "Include": "true"}, {"number": "116", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "117", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "118", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "119", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "120", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "121", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "122", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "123", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "124", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "125", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "126", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "127", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "128", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "129", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "130", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "131", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "132", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "133", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "134", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "135", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "136", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "137", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "138", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "139", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "140", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "141", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "142", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "143", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "144", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "145", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "146", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "147", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "148", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "149", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "150", "ReferenceId": "21779441", "FullCitation": "Zheng R, et al. Genes Cancer (2010) pmid: 21779441", "Include": "true"}, {"number": "151", "ReferenceId": "22375031", "FullCitation": "Lin L, et al. Proc Natl Acad Sci U S A (2012) pmid: 22375031", "Include": "true"}, {"number": "152", "ReferenceId": "18535672", "FullCitation": "Kwei KA, et al. PLoS Genet. (2008) pmid: 18535672", "Include": "true"}, {"number": "153", "ReferenceId": "24476821", "FullCitation": "Nature (2014) pmid: 24476821", "Include": "true"}, {"number": "154", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "155", "ReferenceId": "21720365", "FullCitation": "Nature (2011) pmid: 21720365", "Include": "true"}, {"number": "156", "ReferenceId": "32596145", "FullCitation": "Chen W, et al. Front Oncol (2020) pmid: 32596145", "Include": "true"}, {"number": "157", "ReferenceId": "30674866", "FullCitation": "Liu H, et al. Cell Death Dis (2019) pmid: 30674866", "Include": "true"}, {"number": "158", "ReferenceId": "32103545", "FullCitation": "Wang C, et al. FASEB J (2020) pmid: 32103545", "Include": "true"}, {"number": "159", "ReferenceId": "33300112", "FullCitation": "Plum PS, et al. J Cancer Res Clin Oncol (2021) pmid: 33300112", "Include": "true"}, {"number": "160", "ReferenceId": "23784465", "FullCitation": "Shen F, et al. Oncol. Rep. (2013) pmid: 23784465", "Include": "true"}, {"number": "161", "ReferenceId": "26505174", "FullCitation": "Song Y, et al. Exp Mol Pathol (2015) pmid: 26505174", "Include": "true"}, {"number": "162", "ReferenceId": "30633927", "FullCitation": "Shen W, et al. Hum Pathol (2019) pmid: 30633927", "Include": "true"}, {"number": "163", "ReferenceId": "23313142", "FullCitation": "Tian F, et al. Eur J Cancer (2013) pmid: 23313142", "Include": "true"}, {"number": "164", "ReferenceId": "31092103", "FullCitation": "Ma R, et al. Cancer Biol Ther (2019) pmid: 31092103", "Include": "true"}, {"number": "165", "ReferenceId": "34294813", "FullCitation": "Duan K, et al. Sci Rep (2021) pmid: 34294813", "Include": "true"}, {"number": "166", "ReferenceId": "27325420", "FullCitation": "Martinelli P, et al. Gut (2017) pmid: 27325420", "Include": "true"}, {"number": "167", "ReferenceId": "26841866", "FullCitation": "Varier RA, et al. J. Biol. Chem. (2016) pmid: 26841866", "Include": "true"}, {"number": "168", "ReferenceId": "14651845", "FullCitation": "Hughes_Davies L, et al. Cell (2003) pmid: 14651845", "Include": "true"}, {"number": "169", "ReferenceId": "21409565", "FullCitation": "Cousineau I, et al. Mol. Genet. Genomics (2011) pmid: 21409565", "Include": "true"}, {"number": "170", "ReferenceId": "21735447", "FullCitation": "Wilkerson PM, et al. J. Pathol. (2011) pmid: 21735447", "Include": "true"}, {"number": "171", "ReferenceId": "18787609", "FullCitation": "van Hattem WA, et al. Int J Clin Exp Pathol (2008) pmid: 18787609", "Include": "true"}, {"number": "172", "ReferenceId": "16172393", "FullCitation": "Shih IeM, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 16172393", "Include": "true"}, {"number": "173", "ReferenceId": "23000897", "FullCitation": "Nature (2012) pmid: 23000897", "Include": "true"}, {"number": "174", "ReferenceId": "25631445", "FullCitation": "Nature (2015) pmid: 25631445", "Include": "true"}, {"number": "175", "ReferenceId": "18314909", "FullCitation": "Brown LA, et al. Genes Chromosomes Cancer (2008) pmid: 18314909", "Include": "true"}, {"number": "176", "ReferenceId": "19636701", "FullCitation": "Brown LA, et al. Breast Cancer Res. Treat. (2010) pmid: 19636701", "Include": "true"}, {"number": "177", "ReferenceId": "20349280", "FullCitation": "Altinisik J, et al. Mol. Biol. Rep. (2011) pmid: 20349280", "Include": "true"}, {"number": "178", "ReferenceId": "24641409", "FullCitation": "Madjd Z, et al. Asian Pac. J. Cancer Prev. (2014) pmid: 24641409", "Include": "true"}, {"number": "179", "ReferenceId": "21327470", "FullCitation": "Bane AL, et al. Breast Cancer Res. Treat. (2011) pmid: 21327470", "Include": "true"}, {"number": "180", "ReferenceId": "15355907", "FullCitation": "Rodriguez C, et al. Clin. Cancer Res. (2004) pmid: 15355907", "Include": "true"}, {"number": "181", "ReferenceId": "21487248", "FullCitation": "Dedes KJ, et al. Cell Cycle (2011) pmid: 21487248", "Include": "true"}, {"number": "182", "ReferenceId": "23729402", "FullCitation": "Ihnen M, et al. Mol. Cancer Ther. (2013) pmid: 23729402", "Include": "true"}, {"number": "183", "ReferenceId": "16584130", "FullCitation": "Sridhar J, et al. AAPS J (2006) pmid: 16584130", "Include": "true"}, {"number": "184", "ReferenceId": "16322284", "FullCitation": "Kasugai Y, et al. Clin. Cancer Res. (2005) pmid: 16322284", "Include": "true"}, {"number": "185", "ReferenceId": "28943959", "FullCitation": "Shan YS, et al. Oncol Lett (2017) pmid: 28943959", "Include": "true"}, {"number": "186", "ReferenceId": "31849147", "FullCitation": "Tanaka Y, et al. Cancer Sci (2020) pmid: 31849147", "Include": "true"}, {"number": "187", "ReferenceId": "22885699", "FullCitation": "Schmitz R, et al. Nature (2012) pmid: 22885699", "Include": "true"}, {"number": "188", "ReferenceId": "23079655", "FullCitation": "Choi YJ, et al. Cancer Cell (2012) pmid: 23079655", "Include": "true"}, {"number": "189", "ReferenceId": "23079656", "FullCitation": "Sawai CM, et al. Cancer Cell (2012) pmid: 23079656", "Include": "true"}, {"number": "190", "ReferenceId": "35013097", "FullCitation": "Ketzer F, et al. Oncogenesis (2022) pmid: 35013097", "Include": "true"}, {"number": "191", "ReferenceId": "10525310", "FullCitation": "Xie MH, et al. Cytokine (1999) pmid: 10525310", "Include": "true"}, {"number": "192", "ReferenceId": "25776529", "FullCitation": "Hagel M, et al. Cancer Discov (2015) pmid: 25776529", "Include": "true"}, {"number": "193", "ReferenceId": "12429977", "FullCitation": "Int. J. Oncol. (2002) pmid: 12429977", "Include": "true"}, {"number": "194", "ReferenceId": "23788652", "FullCitation": "Kan Z, et al. Genome Res. (2013) pmid: 23788652", "Include": "true"}, {"number": "195", "ReferenceId": "32111983", "FullCitation": "Li F, et al. Oncogene (2020) pmid: 32111983", "Include": "true"}, {"number": "196", "ReferenceId": "31063779", "FullCitation": "Caruso S, et al. Gastroenterology (2019) pmid: 31063779", "Include": "true"}, {"number": "197", "ReferenceId": "30518874", "FullCitation": "Gao L, et al. Oncogene (2019) pmid: 30518874", "Include": "true"}, {"number": "198", "ReferenceId": "21397858", "FullCitation": "Sawey ET, et al. Cancer Cell (2011) pmid: 21397858", "Include": "true"}, {"number": "199", "ReferenceId": "33674622", "FullCitation": "Kanzaki H, et al. Sci Rep (2021) pmid: 33674622", "Include": "true"}, {"number": "200", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "201", "ReferenceId": "22960745", "FullCitation": "Nature (2012) pmid: 22960745", "Include": "true"}, {"number": "202", "ReferenceId": "28988769", "FullCitation": "Robertson AG, et al. Cell (2017) pmid: 28988769", "Include": "true"}, {"number": "203", "ReferenceId": "22309595", "FullCitation": "Miura S, et al. BMC Cancer (2012) pmid: 22309595", "Include": "true"}, {"number": "204", "ReferenceId": "30815392", "FullCitation": "Kang HJ, et al. Liver Cancer (2019) pmid: 30815392", "Include": "true"}, {"number": "205", "ReferenceId": "25854696", "FullCitation": "Nagamatsu H, et al. Prostate (2015) pmid: 25854696", "Include": "true"}, {"number": "206", "ReferenceId": "31575541", "FullCitation": "Kim RD, et al. Cancer Discov (2019) pmid: 31575541", "Include": "true"}, {"number": "207", "ReferenceId": "27384874", "FullCitation": "Kaibori M, et al. Oncotarget (2016) pmid: 27384874", "Include": "true"}, {"number": "208", "ReferenceId": "31123723", "FullCitation": "Dumbrava EI, et al. JCO Precis Oncol (2018) pmid: 31123723", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_05_02 18:48:29", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "848x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "3 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "SMALL INTESTINE", "disease_ontology": "Duodenum adenocarcinoma", "flowcell_analysis": "2000021447", "gender": "female", "pathology_diagnosis": "adenocarcinoma", "percent_tumor_nuclei": "40", "pipeline_version": "v3.10.2", "purity_assessment": "52.4", "specimen": "ORD_1349720_01*US1297494.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1349720_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Duodenum", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "893.57", "name": "SQ_US1297494.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.813", "cds_effect": "83C>G", "depth": "909", "equivocal": "false", "functional_effect": "missense", "gene": "FLCN", "percent_reads": "81.3", "position": "chr17:17131369", "protein_effect": "P28R", "status": "unknown", "strand": "_", "transcript": "NM_144997", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"allele_fraction": "0.1625", "cds_effect": "892_894delTCT", "depth": "923", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "MYC", "percent_reads": "16.25", "position": "chr8:128752730", "protein_effect": "S298del", "status": "unknown", "strand": "+", "transcript": "NM_002467", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"allele_fraction": "0.4273", "cds_effect": "44C>T", "depth": "440", "equivocal": "false", "functional_effect": "missense", "gene": "SOCS1", "percent_reads": "42.73", "position": "chr16:11349292", "protein_effect": "T15I", "status": "unknown", "strand": "_", "transcript": "NM_003745", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"allele_fraction": "0.2897", "cds_effect": "1370_1372delAGG", "depth": "901", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "DAXX", "percent_reads": "28.97", "position": "chr6:33287880", "protein_effect": "E457del", "status": "unknown", "strand": "_", "transcript": "NM_001350", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"allele_fraction": "0.3521", "cds_effect": "682G>A", "depth": "889", "equivocal": "false", "functional_effect": "missense", "gene": "BRD4", "percent_reads": "35.21", "position": "chr19:15376332", "protein_effect": "V228I", "status": "unknown", "strand": "_", "transcript": "NM_014299", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"allele_fraction": "0.4932", "cds_effect": "1360A>G", "depth": "588", "equivocal": "false", "functional_effect": "missense", "gene": "CUL3", "percent_reads": "49.32", "position": "chr2:225368386", "protein_effect": "M454V", "status": "unknown", "strand": "_", "transcript": "NM_003590", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"allele_fraction": "0.6133", "cds_effect": "1004delG", "depth": "724", "equivocal": "false", "functional_effect": "frameshift", "gene": "TP53", "percent_reads": "61.33", "position": "chr17:7574022", "protein_effect": "R335fs*10", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"allele_fraction": "0.7542", "cds_effect": "65G>C", "depth": "541", "equivocal": "false", "functional_effect": "missense", "gene": "SDHB", "percent_reads": "75.42", "position": "chr1:17380450", "protein_effect": "C22S", "status": "unknown", "strand": "_", "transcript": "NM_003000", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"allele_fraction": "0.2264", "cds_effect": "116C>G", "depth": "773", "equivocal": "false", "functional_effect": "missense", "gene": "SMAD4", "percent_reads": "22.64", "position": "chr18:48573532", "protein_effect": "A39G", "status": "unknown", "strand": "+", "transcript": "NM_005359", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "10", "equivocal": "false", "gene": "FGF3", "number_of_exons": "3 of 3", "position": "chr11:69580315_69683592", "ratio": "2.66", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "CCND3", "number_of_exons": "5 of 5", "position": "chr6:41853880_41956362", "ratio": "2.22", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"copy_number": "17", "equivocal": "false", "gene": "GATA6", "number_of_exons": "6 of 6", "position": "chr18:19751105_19780786", "ratio": "4.47", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"copy_number": "11", "equivocal": "false", "gene": "FGF19", "number_of_exons": "3 of 3", "position": "chr11:69514029_69544517", "ratio": "3.12", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"copy_number": "11", "equivocal": "false", "gene": "CCND1", "number_of_exons": "5 of 5", "position": "chr11:69412013_69502020", "ratio": "3.16", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"copy_number": "40", "equivocal": "false", "gene": "NRAS", "number_of_exons": "5 of 5", "position": "chr1:115211474_115269220", "ratio": "9.85", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"copy_number": "10", "equivocal": "false", "gene": "FGF4", "number_of_exons": "3 of 3", "position": "chr11:69588076_69589852", "ratio": "2.71", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"copy_number": "13", "equivocal": "false", "gene": "FGFR2", "number_of_exons": "18 of 19", "position": "chr10:123197644_123325218", "ratio": "3.29", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}, {"copy_number": "14", "equivocal": "false", "gene": "EMSY", "number_of_exons": "20 of 20", "position": "chr11:76120008_76310898", "ratio": "3.92", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1297494.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "2.52", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}